Association Between Plasma Concentration of Klotho Protein, Osteocalcin, Leptin, Adiponectin, and Bone Mineral Density in Patients with Chronic Kidney Disease

2018 ◽  
Vol 50 (11) ◽  
pp. 816-821 ◽  
Author(s):  
Małgorzata Marchelek-Mysliwiec ◽  
Magda Wisniewska ◽  
Monika Nowosiad-Magda ◽  
Krzysztof Safranow ◽  
Ewa Kwiatkowska ◽  
...  

AbstractPatients with early-stage chronic kidney disease (CKD) are susceptible to changes in metabolic processes. Partial loss of kidney function leads to homoeostatic disturbances in bone and fatty tissue. The aim of this study was to investigate the association between plasma concentrations of Klotho protein, FGF23, leptin, adiponectin, osteocalcin, and bone mineral density (BMD) in patients with CKD in the pre-dialysis period. The study involved 52 patients with CKD and 23 patients with no kidney disease. In both groups, BMD, body mass index and serum or plasma concentrations of lipids, glucose, creatinine, calcium, phosphorus, parathormone, leptin, adiponectin, osteocalcin, Klotho, and FGF23 were measured. The group with CKD had statistically significant higher concentrations of leptin (p<0.001), parathormone (p<0.001), and osteocalcin (p<0.001) in comparison with the control group. Patients with CKD also had statistically significant lower BMD in the femoral neck in comparison with the control group. Osteocalcin correlated negatively with BMD. The results of our study suggest that elevated osteocalcin is the most sensitive marker of decreased bone mass in patients with CKD. Osteocalcin correlated negatively with BMD and GFR. The loss of bone mass in CKD patients was greatest in the femoral neck.

A study was made of phosphorus-calcium metabolism, markers of bone metabolism, bone mineral density in 142 women in the early postmenopausal period, the patients with oxalate nephropathy at stage 2 of chronic kidney disease. It is proved that patients have signs of secondary hyperparathyroidism (hypocalcemia, hypercalciuria, increased parathyroid hormone) and a deficiency of 25 (OH) D3. Violation of bone metabolism is confirmed by a high level of β-Cross Laps and a decrease in bone mineral density. The probability of a 10-year risk of developing osteoporetic fractures in patients using the FRAX calculator is two times higher than in the control group. The conclusion was made that patients with oxalate nephropathy have a high risk of developing osteoporosis already in the early stages of chronic kidney disease.


2020 ◽  
Vol 13 (1) ◽  
pp. 5-12
Author(s):  
Muhammad H. Tariq ◽  
Syed A.S. Sulaiman

Background: Complications of Chronic Kidney Disease (CKD) lead to low bone mass and osteoporosis. Objective: To review the prevalence of osteopenia and osteoporosis among CKD patients. Methods: Potential studies were identified through a systematic search of recognized databases using keywords “prevalence,” “osteopenia,” “osteoporosis,” “Chronic Kidney Disease,” “CKD patients,” “Chronic Renal Failure,” “CRF patients,” “Bone Mineral Density,” and “low bone mass” to identify relevant articles. An article was included in the review if the study met the following criteria: 1) conducted in CKD patients aged 18 years and above, 2) Osteopenia and osteoporosis were determined through Bone Mineral Density (BMD) testing, and 3) T scores were determined for all patients. The studies including transplant patients were not included in this review. Results: A total of 2142 titles were retrieved and of these 8 studies, based on the prevalence of osteopenia and osteoporosis in CKD patients were included in the final review. The review found that the prevalence of osteopenia reported in the studies was between 33.3% and 81% with an average of 45.91% and the prevalence of osteoporosis was between 2.24% and 31.3% with an average of 23.29%. Higher prevalence rates were observed among female gender and CKD patients with low Body Mass Index. Lumbar spine (LS) was found to be the most vulnerable site for osteoporosis among the majority of the studies. Conclusion: The review found a high prevalence rate of osteopenia and osteoporosis among CKD patients. The review further identified that BMD testing at the LS site is more reliable and suitable to determine the risk of fracture and osteoporosis.


2018 ◽  
Vol 33 (suppl_1) ◽  
pp. i499-i499
Author(s):  
Volha Vasilkova ◽  
Tatiana Mokhort ◽  
Elena Naumenko ◽  
Ivan Pchelin ◽  
Valentina Bayrasheva ◽  
...  

2013 ◽  
Vol 98 (5) ◽  
pp. 1930-1938 ◽  
Author(s):  
Michelle R. Denburg ◽  
Anne K. Tsampalieros ◽  
Ian H. de Boer ◽  
Justine Shults ◽  
Heidi J. Kalkwarf ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document